|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1999-6-23
|
|
pubmed:abstractText |
Peripheral blood mononuclear cells (PBMC) from patients who have recovered from visceral leishmaniasis often respond to Leishmania antigens in vitro by production of both IL-4, IFN-gamma and IL-10. In order to establish the cellular sources of these cytokines, we activated cells from individuals with a history of visceral leishmaniasis with Leishmania antigen for 6 days in culture, and identified cytokine production at the single-cell level by flow cytometry. The cytokines were only found in CD3+ cells and among these mainly within the CD4+ subset. The percentage of cytokine-producing cells was compared in Leishmania-activated PBMC cultures from the previous patients and from individuals living in a village where leishmaniasis does not occur. The percentage of IL-10- and IFN-gamma-containing cells was significantly higher in the previous patients than in the controls, indicating that Leishmania-specific T cells producing IL-10 and/or IFN-gamma had been expanded as a result of the infection. The cytokine-producing cells in the previous patients could be divided into three types: (i) cells producing IFN-gamma only; (ii) cells producing IL-4 only; and (iii) cells producing IFN-gamma and IL-10 simultaneously. The first and second group of cells can be described as Th1- and Th2-type cells, respectively. The third group could be a regulatory subset of T cells important for maintaining a balance between Th1- and Th2-type cells in these individuals.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-1534072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-1680337,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-1901883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-2419430,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-3722863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-3935667,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-7546192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-7722314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-7743662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-7748537,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-7899822,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8004809,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8004810,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8097208,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8254019,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8326000,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8423356,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8445253,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8551029,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8580385,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8652043,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8676077,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8757617,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-8763814,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-9267081,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-9338786,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-9380721,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-9393632,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10361241-9469440
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0009-9104
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
500-4
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10361241-Animals,
pubmed-meshheading:10361241-Humans,
pubmed-meshheading:10361241-Interferon-gamma,
pubmed-meshheading:10361241-Interleukin-10,
pubmed-meshheading:10361241-Interleukin-4,
pubmed-meshheading:10361241-Leishmania donovani,
pubmed-meshheading:10361241-Leishmaniasis, Visceral,
pubmed-meshheading:10361241-T-Lymphocyte Subsets,
pubmed-meshheading:10361241-T-Lymphocytes,
pubmed-meshheading:10361241-Th1 Cells,
pubmed-meshheading:10361241-Th2 Cells
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis.
|
|
pubmed:affiliation |
Centre for Medical Parasitology at Laboratory Centre and RHIMA Centre, Copenhagen University Hospital (Rigshospitalet), Denmark. kkcmp@rh.dk
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
